Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

• D. Lüftner,
• H. Tesch,
• M. Schmidt,
• A. Hartkopf,
• S. Streicher,
• A. Resch,
• L. Genovese,
• C. Rosé,
• R. Valenti,
• N. Harbeck

Affiliations

D. Lüftner

H. Tesch

M. Schmidt

A. Hartkopf

S. Streicher

A. Resch

L. Genovese

C. Rosé

R. Valenti

N. Harbeck